SENS vs. TXG, TRNS, CTKB, EYPT, LAB, ALNT, QSI, AEHR, QTRX, and MASS
Should you be buying Senseonics stock or one of its competitors? The main competitors of Senseonics include 10x Genomics (TXG), Transcat (TRNS), Cytek Biosciences (CTKB), EyePoint Pharmaceuticals (EYPT), Standard BioTools (LAB), Allient (ALNT), Quantum-Si (QSI), Aehr Test Systems (AEHR), Quanterix (QTRX), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry.
Senseonics vs.
Senseonics (NYSE:SENS) and 10x Genomics (NASDAQ:TXG) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, community ranking, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.
In the previous week, 10x Genomics had 13 more articles in the media than Senseonics. MarketBeat recorded 13 mentions for 10x Genomics and 0 mentions for Senseonics. 10x Genomics' average media sentiment score of 1.02 beat Senseonics' score of 0.00 indicating that 10x Genomics is being referred to more favorably in the news media.
10x Genomics has a net margin of -29.90% compared to Senseonics' net margin of -362.30%. 10x Genomics' return on equity of -25.40% beat Senseonics' return on equity.
10x Genomics received 57 more outperform votes than Senseonics when rated by MarketBeat users. Likewise, 51.26% of users gave 10x Genomics an outperform vote while only 10.81% of users gave Senseonics an outperform vote.
Senseonics has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 1.93, suggesting that its share price is 93% more volatile than the S&P 500.
Senseonics presently has a consensus target price of $2.00, indicating a potential upside of 167.74%. 10x Genomics has a consensus target price of $20.21, indicating a potential upside of 94.56%. Given Senseonics' stronger consensus rating and higher possible upside, research analysts plainly believe Senseonics is more favorable than 10x Genomics.
12.4% of Senseonics shares are held by institutional investors. Comparatively, 84.7% of 10x Genomics shares are held by institutional investors. 3.6% of Senseonics shares are held by insiders. Comparatively, 10.0% of 10x Genomics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Senseonics has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Senseonics, indicating that it is currently the more affordable of the two stocks.
Summary
10x Genomics beats Senseonics on 12 of the 18 factors compared between the two stocks.
Get Senseonics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SENS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Senseonics Competitors List
Related Companies and Tools
This page (NYSE:SENS) was last updated on 3/24/2025 by MarketBeat.com Staff
Buy SENS Stock Free SENS Stock Alerts